Sex Hormones in Postmenopausal Women with Breast Cancer on Tamoxifen

Hormone Research in Paediatrics

Volumn 47, Issue 3, 1997, Pages 116-120

  Kostoglou Athanaou, Ifigenia ^a   Ntalles, Konstantinos ^a   Gogas, John ^b   Markopoulos, Christos ^b   Alevizou Terzaki, Vassiliki ^c   Athanassiou, Panagiotis ^d   Georgiou, Evangelos ^a   Proukakis, Charalambos ^a  

^a Department of Medical Physics ^*  (Ukraine)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c LAIKO GENERAL HOSPITAL   (Greece)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Sex hormones; Tamoxifen

Indexed keywords

ANDROSTENEDIONE; ANTIESTROGEN; ESTRADIOL; FOLLITROPIN; HYDROXYPROGESTERONE; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; PROTIRELIN; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TESTOSTERONE;

ADULT; AGED; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; LONG TERM CARE; LUTEINIZING HORMONE BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; FOLLICLE STIMULATING HORMONE; GONADAL STEROID HORMONES; HUMANS; LUTEINIZING HORMONE; MENOPAUSE; MIDDLE AGED; PROLACTIN; SEX HORMONE-BINDING GLOBULIN; TAMOXIFEN;

EID: 0031043180     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000185445     Document Type: Article

References (41)

1. Lcmcr IJ. Jordan VC: Development of antics-trogens and their use ir. breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 1990:50:4177-4189.
2. Cuzick J, Wang DY, Butbrook RD: The prevention of breast cancer. Lancet 1986:1:83-86.
3. Love RR. Mazess RB. Barden US. Epstein S. Newcomb PA. Jordan VC. Carbone PP. De-Mets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992:326:852-856.
4. Cuzick J, Allen D, Baum M, Barrett J, Clark G, Kakkar V, Melissari E, Moniz C, Moore J, Parsons V: Long-term effects of tamoxifen. Biological Effects of Tamoxifen Working Party. Eur J Cancer 1993:29:15-21.
5. Jordan VC. Koerner S. Robinson C: Inhibition of estrogen stimulated prolactin release by an-ticstrogens. J Endocrinol 1975;65:151-152.
6. Colder MP. Philip MEA. Fahmy DR. Preecc PE. Jones V. Henk JM. Griffiths K: Plasma hormones in patients with advanced breast cancer treated with tamoxifen. Eur J Cancer 1976:12:719-723.
7. Sakai F. Chcix F. Clavel M. Colon J. Mayer M. Pommatau E. Saez S: Increases in steroid binding globulin induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol 1978:76:219-226.
8. Szamel I. Herman I. Borvendeg J. Vincze B. Ilindy I. Eckhardt S: Effect of tamoxifen treatment on the TRH-induced prolactin release in patients with breast cancer. Cancer Treat Rep 1979:63:1202-1205.
9. Szamel I. Hermann I. Borvendeg J. Vincze B. Hindy I. Kerpcl-Fronius S: The influence of antioestrogen tamoxifen treatment on the scrum prolactin levels in patients with breast cancer. Acta Med Hung 1979:36:341-344.
10. Fcx G. Adielsson G. Mattson W: Oestrogen like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocrinol 1981: 97:109-113.
11. Paterson AG, Turkes A, Groom GV, Webster DFR: The effect of tamoxifen on plasma growth hormone and prolactin in postmenopausal women with advanced breast cancer. EurJ Cancer Clin Oncol 1983;19:919-922.
12. Pomander T. Rutqvist IE. Wilking N. Carl-strom K. von Schoultz B: Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer. Eur J Cancer 1993;29:497-500.
13. Bland MJ. Altman DG: The use of transformation when comparing two means. BMJ 1996; 312:1153.
14. Goldcr MP. Philips MEA. Baum M. Griffiths K. Fahmy DR. Henk JM. Jones V. Preece PE: Hormones in breast cancer patients on tamoxifen. Br J Cancer 1975;32:246-247.
15. Willis KJ. London DR. Ward HWC. Butt WR. Lynch SS. Rudd BT: Recurrent breast cancer treated with the antiestrogcn tamoxifen: Correlation between hormonal changes and clinical course. BrMedJ 1977:1:425-428.
16. Tanaka M. Abe K. Ohnami S. Adachi I. Vaga-muchi K. Miyakawi S: Tamoxifen in advanced breast cancer: Response rate, effect on pituitary hormone reserve and binding affinity to estrogen receptor. Jpn J Clin Oncol 1978:8:141-148.
17. Manni A. Trujillo JE. Marshall JS. Brodkev J. Pearson OH: Anlihormone treatment of stage IV breast cancer. Cancer 1979:43:444-450.
18. Pruitt BT. Tormev DC. Rose DP. Witte RS. Falkson G: Trioxifene mesylate: Investigation of activity in human breast cancer and comparison with tamoxifen of endocrine effects. Clin Res 1981:29:763.
19. Coombes RC. Powlcs TJ. Rees LH. Ratcliffe WA. Nash AG. Henk M. Ford HT. Gazct JC. Neville AM: Tamoxifen, aminoglutethimidc and danazol: Effect of therapy on hormones in postmenopausal patients with breast cancer. Br J Cancer 1982;46:30-34.
20. Hclgason S. Wilking N. Carlstrom K. Damher MG. von Schoultz B: A comparative study of the estrogenic effects of tamoxifen and 17(3-estradiol in postmenopausal women. J Clin Endocrinol Metab 1982:54:404-408.
21. Groom GV. Griffiths K: Effect of the antiestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal prc-menopausal women. J Endocrinol 1976:70:421-428.
22. Sherman BM, Chapler FK, Crickard K, Wv-koff D: Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 1979:63:398-404.
23. King DT, Kennedy RJ: Tamoxifen antiestrogcn therapy in advanced breast cancer. Ann Intern Med 1977:87:687-690.
24. Szamel I. Vincre B. Hindv I. Hermann I. Bor-vendeg J. Eckhardt S: Hormonal changes during a prolonged tamoxifen treatment in patients with advanced breast cancer. Oncology 1986:43:7-11.
25. Marchesoni D. Mozzancga B. Gangcmi M. En-richi M: Tamoxifen in the therapy of postmenopausal endometrial cancer: Variations in some hormonal parameters. Eur J Gynaecol Oncol 1980:1:1116-1121.
26. Ohgo S. Kato Y. Chihara K. Imura H: Plasma prolactin responses to thvrotropin-releasing hormone in patients with breast cancer. Cancer 1976:37:1412-1416.
27. Angcli A. Dogliotti L: Fibrocystic disease of the breast. A revisit and new perspectives. Excerp-ta Med 1984:15-37.
28. Holtkamp W. Nagel GA. Michel U. Rauschek-cr H: Pathophysiologie der Hyperprolaktina-mic beim Mammarkarzinom. Onkologie 1988: 11:86-103.
29. Wang DY, Hampson S, Kwa HG, Moore JW, Bulbrook RD, Fentiman IS, Hayward JL, King RJB, Millis RR, Rubens RD, Allen DS: Scrum prolactin levels in women with breast cancer and their relationship to survival. Eur J Cancer Clin Oncol 1986;22:487-492.
30. Holtkamp W. Osterloh B. Rauschcckcr H. Nagel GA: Mastectomy stimulates prolactin release in breast cancer patients. Anticancer Res 1986:6:725-727.
31. Pannuti F. Martoni A. Farabegoli G. Piana F.: Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments. Chemotera-pia 1985:4:127-134.
32. Van der Geest S. Slkiter WJ. Doorenbos H: The effect of tamoxifen on TRH induced prolactin response in postmenopausal women with metastatic mammary cancer. Rev Endocr Re-lat Cancer 1981;9:251-258.
33. Willis KJ. London DR. Butt WR: Hormonal effects of tamoxifen in women with carcinoma of the breast. J Endocrinol 1976:69:51.
34. Daxcnbichler G. Margetter R. Dapunt O: Changes in scrum hormone levels after tamoxifen treatment. Cancer Treat Rep 1979:63: 1213-1217.
35. Ranee NE. Young WS III: Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology 1991:128: 2239-2247.
36. Friend KE. Chiou YK. Lopes MBS. Laws ER Jr. Hughes KM. Shupnik MA: Estrogen receptor expression in human pituitary: Correlation with immunohistochemistry in normal tissue and immunohistochemistry and morphology in macroadenomas. J Clin Endocrinol Metab 1994;78:1497-1504.
37. van den Kocdiik CDM. Blankenstein MA. Thijsscn JHH: Speculation on the mechanism of action of triphenvlethylene antioestrogens. Biochem Pharmacol 1994;47:1927-1937.
38. Mercicr-Bodard C. Radanvi C. Roux C. Grover M. Robcl P. Dadoune JP. Petra PH. Jolly DJ. Baulicu EE: Cellular distribution and hormonal regulation of H-SBP. J Steroid Biochem 1987;27:297-307.
39. Mercicr-Bodard C. Nivct V. Baulieu EE: Effects of hormones on SBP mRNA levels in human cancer cells. J Steroid Biochem Mol Biol 1991:40:777-785.
40. Andcrsson M. Storm I. Mouridsen HT: Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991:83: 1013-1017.
41. Fomander T. Rutqvist LE. Wilking N: Effects of tamoxifen on the female genital tract. Ann NY Acad Sci 1991;622:469-476.